Drug
Mavorixafor clinical trials
Also written X4P-001 and AMD11070.
- studies test it
- 13
- open now
- 1
- in phase 3
- 2
- first study started
- 2004
Keep track of what changes. Save the mavorixafor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
13 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2016 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
X4 Pharmaceuticals (10) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Genzyme, a Sanofi Company (1) · Abbisko Therapeutics Co, Ltd (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses mavorixafor is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsRecruitingPhase 3X4 PharmaceuticalsNCT06056297Written as Mavorixafor
- A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic FunctionCompletedPhase 1X4 PharmaceuticalsNCT06858696Written as Mavorixafor
- Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeCompletedPhase 3X4 PharmaceuticalsNCT03995108Written as Mavorixafor
- A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia DisordersCompletedPhase 1/2X4 PharmaceuticalsNCT04154488Written as Mavorixafor
- Drug-Drug Interaction Potential of MavorixaforCompletedPhase 1X4 PharmaceuticalsNCT06914869Written as Mavorixafor
- A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeCompletedPhase 2X4 PharmaceuticalsNCT03005327Written as X4P-001
- A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4CompletedPhase 1X4 PharmaceuticalsNCT04274738Written as Mavorixafor
- Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaTerminatedPhase 1/2X4 PharmaceuticalsNCT02923531Written as X4P-001
- Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected PatientsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00089466Written as AMD11070
- A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBCStatus unknownPhase 1/2Abbisko Therapeutics Co, LtdNCT05103917Written as X4P-001
- X4P-001 and Pembrolizumab in Patients With Advanced MelanomaCompletedPhase 1X4 PharmaceuticalsNCT02823405Written as X4P-001
- A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy VolunteersTerminatedPhase 1X4 PharmaceuticalsNCT02680782Written as X4P-001
- A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic VirusCompletedPhase 1Genzyme, a Sanofi CompanyNCT00361101Written as AMD11070
Given in every arm · 2 — mavorixafor is usual care beside what is tested
- Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaCompletedPhase 1/2X4 PharmaceuticalsNCT02667886Written as X4P-001
- Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected MenCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00063804Written as AMD070
Codes
What other systems call mavorixafor · ClinicalTrials.gg INT004728
- MeSH (NLM) C494414mavorixaforConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0G9LGB5O2WMAVORIXAFORConfirmed FDA, NLM, Wikidata
- Wikidata Q27074430mavorixaforConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C126660MavorixaforOne source FDA
- DrugBank DB05501One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C494414 | mavorixafor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0G9LGB5O2W | MAVORIXAFOR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074430 | mavorixafor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C126660 | Mavorixafor | One source FDA |
| DrugBank | DB05501 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.